PatientView

‘Patient Groups: A Seat at the Pricing Table’ is now available The latest global research explores how patient groups are participating in pricing, reimbursement & access discussions worldwide. Visit patientview.com or contact [email protected] to find out more.

Tomorrow, PatientView will release research that examines the actions & advocacy of patient groups to gain access to medicines. ‘Patient Groups: A Seat at the Pricing Table’, will draw on insights from 2,262 patient groups. Contact [email protected] for more info

PatientView’s latest Corporate Reputation of Pharma 2025 reports reveal how 282 patient groups across ANZ, China, & Japan perceive the pharma industry. Separate reports are available for ANZ, China, and Japan. For further information, visit patient-view.com/press-relea…

Today, PatientView has released the Neurology Edition of ‘The Corporate Reputation of Pharma, 2025-2026’, alongside two separate reports covering Neurodegenerative Conditions and Multiple Sclerosis (MS). More information can be found in the press release tinyurl.com/bp6myhwx

The Corporate Reputation of Pharma 2025/26, Cancer Edition is now available. The report captures the perspectives of 505 Cancer patient groups & features the performance of 31 pharma and biotech companies. Read the Press Release: tinyurl.com/bp6myhwx

How effective are 4 key pharma companies at involving patients or patient groups in the co-design of Real-World Evidence studies? This is Question 3ii of the freely available ‘What Companies Say, 2025-2026’ PatientView report. Access here:  tinyurl.com/3cckuapz

𝗪𝗼𝗿𝗹𝗱 𝗣𝗿𝗼𝘀𝘁𝗮𝘁𝗲 𝗖𝗮𝗻𝗰𝗲𝗿 𝗗𝗮𝘆: 𝗪𝗵𝘆 𝗴𝗹𝗼𝗯𝗮𝗹 𝗮𝗰𝘁𝗶𝗼𝗻 𝗶𝘀 𝗻𝗲𝗲𝗱𝗲𝗱 Prostate cancer's the most commonly diagnosed cancer in men in 100+ countries, yet approaches to screening, diagnosis, & care remain inconsistent. Read more:tinyurl.com/2p9jafta

Today, the Corporate Reputation of Pharma 2025/26, Canada Edition has been published. For more information, including industry-wide findings and the top-ranking pharma companies in Canada, read the press release: patient-view.com/press-relea…

ViiV Healthcare has ranked #1 for the 13th consecutive year in the PatientView Corporate Reputation of Pharma survey. Given the company’s consistently high rankings, we recently spoke with Ama Appiah, Patient Affairs Lead, at ViiV Healthcare. Read the Q&A: tinyurl.com/yskv2mxf

“How do four key pharma companies address R&D demands from patient groups?” Find answers to this question in 'What Companies Say 2025-2026', with contributions from Boehringer Ingelheim, Novartis, Servier, and ViiV Healthcare. Access the publication here: tinyurl.com/39fkur6h

Friday 15th – USA press release The Corporate Reputation of Pharma 2025/26 - USA Edition is now available To learn more about the changes in the corporate reputation of the US pharma industry and individual pharma companies, read the press release: patient-view.com/press-relea…